Han K Chang

US Patent:

20220195046, Jun 23, 2022

Filed:

Mar 27, 2020

Appl. No.:

17/599433

Inventors:

- Princeton NJ, US
Nathan O. SIEMERS - Pacific Grove CA, US
Dimple PANDYA - Princeton NJ, US
Han CHANG - West Windsor NJ, US
Teresa K. SANCHEZ - Princeton NJ, US
Christopher T. HARBISON - Hamilton NJ, US
Peter M. SZABO - Pennington NJ, US
Zachary S. BOYD - Skillman NJ, US
Xiaozhong QIAN - Pennington NJ, US
Samy Abdel SACI - Lawrenceville NJ, US
Tina C. YOUNG - Lawrence Township NJ, US
Sujaya SRINIVASAN - Princeton Junction NJ, US
Megan M. WIND-ROTOLO - Newtown PA, US
Jasmine RIZZO - Edison NJ, US
Donald G. JACKSON - Hopkinton MA, US
Alice M. WALSH - Glenside PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07K 16/28
A61P 35/00

Abstract:

The disclosure provides a method for treating a subject afflicted with a tumor comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or anti-gen-binding portion thereof, wherein the subject is identified as having a high inflammatory gene signature score and a tumor that has a high tumor mutation burden (TMB) status. In some embodiments, the high inflammatory gene signature score is determined by measuring the expression of a panel of inflammatory genes in a tumor sample obtained from the subject, wherein the inflammatory gene panel comprises CD274 (PD-L1), CD8A, LAG3, and STAT1.

Address:

1534 Oakley Ln, Hanover, MD 21076

VIN:

JTHBJ46G872113371

Make:

LEXUS

Model:

ES 350

Year:

2007